CA2182771A1 - Derives de 11-(phenyle substitue)-estra-4,9-diene - Google Patents

Derives de 11-(phenyle substitue)-estra-4,9-diene

Info

Publication number
CA2182771A1
CA2182771A1 CA002182771A CA2182771A CA2182771A1 CA 2182771 A1 CA2182771 A1 CA 2182771A1 CA 002182771 A CA002182771 A CA 002182771A CA 2182771 A CA2182771 A CA 2182771A CA 2182771 A1 CA2182771 A1 CA 2182771A1
Authority
CA
Canada
Prior art keywords
estra
substituted phenyl
ring
residue
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002182771A
Other languages
English (en)
Other versions
CA2182771C (fr
Inventor
Ronald Gebhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pop Test Cortisol LLC
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2182771(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of CA2182771A1 publication Critical patent/CA2182771A1/fr
Application granted granted Critical
Publication of CA2182771C publication Critical patent/CA2182771C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002182771A 1995-08-17 1996-08-06 Derives de 11-(phenyle substitue)-estra-4,9-diene Expired - Fee Related CA2182771C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95202229.1 1995-08-17
EP95202229 1995-08-17

Publications (2)

Publication Number Publication Date
CA2182771A1 true CA2182771A1 (fr) 1997-02-18
CA2182771C CA2182771C (fr) 2007-04-24

Family

ID=8220570

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002182771A Expired - Fee Related CA2182771C (fr) 1995-08-17 1996-08-06 Derives de 11-(phenyle substitue)-estra-4,9-diene

Country Status (25)

Country Link
US (1) US6011025A (fr)
EP (1) EP0763541B1 (fr)
JP (1) JP3977462B2 (fr)
KR (1) KR100445376B1 (fr)
CN (1) CN1129602C (fr)
AR (1) AR003982A1 (fr)
AT (1) ATE182596T1 (fr)
AU (1) AU711369B2 (fr)
BR (1) BR9603429A (fr)
CA (1) CA2182771C (fr)
CZ (1) CZ287740B6 (fr)
DE (1) DE69603425T2 (fr)
DK (1) DK0763541T3 (fr)
ES (1) ES2137625T3 (fr)
GR (1) GR3031116T3 (fr)
HU (1) HU229023B1 (fr)
IL (1) IL118974A (fr)
NO (1) NO306257B1 (fr)
NZ (1) NZ299181A (fr)
PL (1) PL183468B1 (fr)
RU (1) RU2135514C1 (fr)
SG (1) SG52834A1 (fr)
TR (1) TR199600664A2 (fr)
TW (1) TW464654B (fr)
ZA (1) ZA966555B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (fr) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
CN1187053C (zh) * 1997-10-06 2005-02-02 利兰·斯坦福青年大学托管委员会 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
EP1726307A3 (fr) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methodes de traitement de la psychose associee a un dysfonctionnement lie aux glucocorticoides
IL139672A (en) 1998-05-15 2005-11-20 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the tretment of dementia
US6756366B1 (en) * 1999-04-06 2004-06-29 Akzo Nobel N.V. Orally active androgens
WO2002064550A1 (fr) * 2001-02-14 2002-08-22 Abbott Laboratories Modulateurs des recepteurs des glucocorticoides
EP1285927A3 (fr) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Utilisation d'antagonistes du récepteur glucocorticoide pour la prévention et traitement des maladies de la fonction reproductive masculine
PT1652526E (pt) * 2001-10-26 2009-02-06 Organon Nv Utilização de (11β,17β)-11-(1,3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)-estra-4,9-dien-3-ona no tratamento de desordem depressiva grave
AU2002366217A1 (en) 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
EP1581234A4 (fr) * 2002-11-05 2007-09-12 Corcept Therapeutics Inc Procédés pour traiter la migraine
US20040229855A1 (en) * 2003-02-04 2004-11-18 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
TW200820977A (en) 2006-08-08 2008-05-16 Organon Nv Use of glucocorticoid receptor antagonists for treatment of infectious conditions
EP2671086B1 (fr) * 2011-02-03 2018-04-25 Pop Test Oncology LLC Système et méthode de diagnostic et de traitement
WO2012129305A1 (fr) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Polythérapie
US8865693B2 (en) 2011-03-31 2014-10-21 Pop Test Cortisol Llc Prevention of infection
EP2699245A4 (fr) * 2011-04-18 2014-12-10 Pop Test Cortisol Llc Traitement contre la perte des cheveux
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
US9662392B2 (en) 2014-06-03 2017-05-30 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
WO2016140867A1 (fr) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Utilisation d'un antagoniste du récepteur des glucocorticoïdes et d'analogues de la somatostatine pour le traitement de tumeurs secrétant de l'hormone adrénocorticotrope (acth)
WO2016154203A1 (fr) * 2015-03-23 2016-09-29 Evestra, Inc. Nouveaux agents cytotoxiques qui ciblent préférentiellement le facteur d'inhibition de la leucémie (lif) pour le traitement de tumeurs malignes et comme nouveaux agents contraceptifs
US10610534B2 (en) 2015-03-30 2020-04-07 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3400233B1 (fr) * 2015-08-03 2025-10-22 Pop Test Oncology LLC Compositions pharmaceutiques et méthodes
US9598459B2 (en) * 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112902A1 (fr) * 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibiteurs de récepteurs glucocorticoïdes
KR102197526B1 (ko) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 이소성 쿠싱 증후군의 감별 진단
PL3523315T3 (pl) * 2016-10-07 2021-10-18 Oric Pharmaceuticals, Inc. Inhibitor receptora glukokortykoidowego
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
US4780461A (en) * 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) * 1987-05-19 1988-12-01 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
DE59010853D1 (de) * 1989-08-04 1998-12-03 Schering Ag 11 Beta-Aryl-gona-4,9-dien-3-one
EP0712311B1 (fr) * 1993-08-04 1998-10-07 Akzo Nobel N.V. Steroides antiglucocorticoides destines au traitement de troubles associes a l'anxiete
ATE156836T1 (de) * 1994-05-19 1997-08-15 Akzo Nobel Nv 11,21-bisphenyl-19-nor-pregnan derivate

Also Published As

Publication number Publication date
AU711369B2 (en) 1999-10-14
CZ287740B6 (en) 2001-01-17
KR970010784A (ko) 1997-03-27
GR3031116T3 (en) 1999-12-31
NO306257B1 (no) 1999-10-11
EP0763541A1 (fr) 1997-03-19
DK0763541T3 (da) 2000-02-28
KR100445376B1 (ko) 2004-11-08
ES2137625T3 (es) 1999-12-16
MX9603476A (es) 1997-07-31
JP3977462B2 (ja) 2007-09-19
HUP9602269A2 (en) 1997-04-28
CZ238696A3 (en) 1997-05-14
ZA966555B (en) 1997-02-19
HU229023B1 (en) 2013-07-29
DE69603425T2 (de) 2000-01-20
HK1002010A1 (en) 1998-07-24
CA2182771C (fr) 2007-04-24
NO963427D0 (no) 1996-08-16
US6011025A (en) 2000-01-04
RU2135514C1 (ru) 1999-08-27
ATE182596T1 (de) 1999-08-15
EP0763541B1 (fr) 1999-07-28
DE69603425D1 (de) 1999-09-02
AU6211996A (en) 1997-02-20
BR9603429A (pt) 1998-05-12
TW464654B (en) 2001-11-21
JPH09104696A (ja) 1997-04-22
PL183468B1 (pl) 2002-06-28
IL118974A0 (en) 1996-10-31
CN1129602C (zh) 2003-12-03
SG52834A1 (en) 1998-09-28
IL118974A (en) 2001-09-13
PL315733A1 (en) 1997-03-03
CN1147520A (zh) 1997-04-16
NZ299181A (en) 1997-09-22
TR199600664A2 (tr) 1997-03-21
HU9602269D0 (en) 1996-10-28
NO963427L (no) 1997-02-18
AR003982A1 (es) 1998-09-30
HUP9602269A3 (en) 1997-12-29

Similar Documents

Publication Publication Date Title
KR970010784A (ko) 11-(치환된 페닐)-에스트라-4,9-디엔 유도체
TW263499B (fr)
GR3017996T3 (en) 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION.
RU96115774A (ru) Производные 11-(замещенный фенил)-эстра-4,9-диена
CA2084431A1 (fr) Steroides 17-spirofuran-3'-ylidene
NO20002676L (no) Androgene steroidforbindelser og en fremgangsmÕte for fremstilling og anvendelse av samme
CA2250191A1 (fr) Benzothiofenes, formulations dans lesquelles ils entrent et techniques
JPS5283379A (en) Synthesis of carbostyril derivatives
NO138808C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pregnansyrederivater
GR3023427T3 (en) Heteroarylmethylbenzols aromatase inhibitors
JPS5585520A (en) Remedy for peptic ulcer
JPS52106824A (en) Preparation of molybdenum-containing compounds
IE39800B1 (en) 4-amino-3-hydrazino-1 2 4-triazole derivatives methods fortheir preparation and compositions containing them
JPS51136676A (en) Process for preparation of carbostyril derivatives
BG102238A (en) New imidazoline-2,4-dions of anticonvulsion effect containing, in the first place, orthosubstituted ar(alk)yl radical, and method for their preparation
JPS5293771A (en) Benzotriazoles
GB1515017A (en) 2',3'-dihydroestra-1,3,5(10)-trieno-(16alpha,17alpha-b)furan-17beta-ols
JPS53127466A (en) Thiocarbamate type heterocyclic compounds and its preparation
JPS5412385A (en) Carbostyril derivative
JPS51141880A (en) Process for preparing carbostyril derivatives
JPS51128977A (en) Process for preparing carbostyril derivatives
JPS51128979A (en) Process for preparing carbostyril derivatives
JPS5589299A (en) Novel estradiol derivative, its preparation, and antitumor agent
JPS51128976A (en) Process for preparing carbostyril derivatives
GB1152672A (en) 11-Oxygenated-16-methylene-17alpha-alkoxy Steroids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160808